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infection and residual changes remains difﬁcult,
which is a drawback during follow-up of the
effect of treatment.
Scintigraphic imaging allows delineation of foci
localised in all parts of the body, based on
functional changes of tissues. FDG-PET, an estab-
lished imaging tool in oncology, is now being
used for the diagnosis of clinical infectious dis-
eases. After cellular uptake, FDG, an analogue of
glucose, is trapped metabolically and provides an
image which portrays glucose utilisation. Inﬂam-
matory cells take up large amounts of glucose as a
result of an increased metabolic rate [8]. Previ-
ously, FDG-PET has proved valuable in diagno-
sing soft tissue infections, osteomyelitis,
intravascular infections and fever of unknown
origin [9,10]. Compared with conventional nuc-
lear medicine techniques (67gallium citrate and
labelled leukocytes), the advantages of FDG-PET
are early imaging and higher spatial resolution,
resulting in more anatomical information [11].
Overall, FDG-PET appears to be a promising new
imaging technique that enables early identiﬁca-
tion of the sites of disseminated Candida infection,
as well as allowing the effect of antifungal
treatment to be evaluated.
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ABSTRACT
Predisposing factors, antimicrobial susceptibility
patterns, treatment and outcome were analysed
for nine consecutive patients with nocardiosis.
Predisposing factors were identiﬁed in six (67%)
of the nine patients. Clinical syndromes of nocar-
dial infection were pulmonary infection (three
patients), cerebral infection (ﬁve patients) and
disseminated infection (one patient). The pre-
dominant (60%) species was Nocardia farcinica
rather than the Nocardia asteroides complex. Treat-
ment was started empirically, modiﬁed according
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to the antimicrobial susceptibility pattern, and
then continued for 6–12 months. Overall mortal-
ity was 33%, with death being caused by the
Nocardia infection in two cases.
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Nocardiosis ranges from a self-limited, sub-clin-
ical process to acute life-threatening, dissemin-
ated disease [1]. Pulmonary infection is the most
common presentation, with dissemination to
multiple sites in the body, especially the brain
[2,3]. Nocardia spp. cause infection in both normal
and immunocompromised hosts [1,2,4]. In immu-
nocompetent individuals, therapy for 6 months
usually results in complete cure without relapse,
but the appropriate length of therapy is not
established for immunocompromised hosts. The
purpose of this study was to examine the pre-
disposing factors, clinical features, radiological
ﬁndings, antimicrobial susceptibility patterns,
treatment and outcome for patients with nocar-
diosis.
A retrospective study was performed in the
Department of Infectious Diseases at Erciyes
University Hospital between January 2001 and
February 2004. Clinical records were reviewed
and all cultures positive for Nocardia spp. were
sent to the Faculte´ de Pharmacie, Universite´
Claude-Bernard, France, for susceptibility testing
by disk diffusion and further identiﬁcation by 16S
rDNA sequence analysis as described previously
[5–7]. Nocardiosis was deﬁned on the basis of a
positive culture and a consistent clinical presen-
tation. Localised infection was deﬁned as involve-
ment of only one organ, whereas disseminated
infection was deﬁned as involvement of two or
more non-contiguous sites [8]. Treatment was
started empirically with ceftriaxone (4 g ⁄day)
plus amikacin (1 g ⁄day), and was then modiﬁed
according to the susceptibility pattern and the
Table 1. Clinical characteristics of patients with nocardiosis
Case no. Diagnosis Underlying condition Immunosuppressive drug Nocardia spp. Management Treatment duration Outcome
1 Pulmonary Renal
transplant
DM
MMF
MP
N. farcinica Ceftriaxone + amikacina
imipenemb
Co-amoxc
6 months Cure
2 Disseminated
(pulmonary and
cerebral)
Bullous
pemphigoid
DM
MP N. farcinica Ceftriaxone + amikacina
meropenemb
Co-amoxc
surgery
37 days Relapse,
death
3d Pulmonary Renal
transplant
MMF
MP
Cyclosporine
N. cyriacigeorgicae Ceftriaxone + amikacina,
teicoplanin
TMP-SMXc
70 days Death
4 Cerebral Renal
transplant
MMF
MP
Cyclosporine
N. cyriacigeorgicae Ceftriaxone + amikacina,
TMP-SMXc
6 months Cure
5 Pulmonary Renal
transplant
MMF
MP
N. cyriacigeorgicae Ceftriaxone + amikacina 20 days Death
6 Cerebral None None N. farcinica Ceftriaxone + amikacina,
meropenemb,
Co-amoxc,
surgery
6 months Cure
7 Cerebral None None N. farcinica Ceftriaxone + amikacina,
Co-amoxc,
surgery
6 months Cure
8 Cerebral None None N. farcinica Ceftriaxone + amikacina,
meropenemb,
Co-amoxc,
surgery
12 months Relapse,
cure
9 Cerebral SLE Azathioprine
MP
N. arthritidise Ceftriaxone + amikacina,
TMP-SMXc
surgery
12 months Relapse,
cure
aInitial intravenous antimicrobial therapy.
bTherapy was directed by in-vitro antimicrobial susceptibility results.
cIntravenous therapy was switched to oral treatment.
dThis patient was coinfected with methicillin-resistant Staphylococcus aureus as a second pathogen and treated with teicoplanin.
eSubgroup of N. asteroides complex.
MMF, mycophenolate mophetil; MP, methylprednisolone; DM, diabetes mellitus; SLE, systemic lupus erythematosus; Co-amox, amoxycillin–clavulanate; TMP-SMX,
trimethoprim–sulphamethoxazole.
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outcome. Intravenous therapy was continued for
30 days and then replaced by oral treatment for a
maximum of 6–12 months. Cure was deﬁned as
clinical improvement and ⁄ or resolution of the
microbiological ﬁndings at the end of the treat-
ment period. Relapse was deﬁned as initial
improvement followed by the recurrence of clin-
ical symptoms and ⁄ or concomitant isolation of
Nocardia spp. [9,10].
During the 3-year study period, Nocardia was
isolated from nine patients (three females) with
an average age of 31.2 ± 15.1 years (27.3 ±
6.1 years for females and 33.2 ± 18.3 years for
males). Clinical details are summarised in
Table 1. The most common symptoms were fever,
cough, purulent expectoration, dyspnoea, chest
pain and night sweats. Gram’s stain and modiﬁed
acid-fast stain of bronchoscopy ﬂuid or sputum
was positive in all cases. Chest radiograph and
computerised tomography (CT) results were
variable in three cases, showing left lower lobe
shadowing, right lower lobe shadowing, and a
large pulmonary nodule on the left lower lobe.
One of these patients developed fatal nosocomial
pneumonia with methicillin-resistant Staphylococ-
cus aureus as a second pathogen.
Five patients had a cerebral abscess diagnosed
by culture of pus aspirated from the brain. The
major presenting symptoms were nausea and
vomiting, loss of consciousness, headache, con-
vulsion and fever. Contrast-enhanced CT brain
scans showed a large lesion in the left frontal lobe
(two patients), a small lesion in the left thalamic
area, multiple lesions in the left parietal lobe and
a lesion with marked peripheral oedema in the
right temporal lobe. Four patients underwent
cranial surgery, and their abscesses, including
the capsule, were completely excised. In two
patients, the diagnosis of nocardiosis was based
on a CT-guided stereotactic needle aspiration of
brain abscess. An aspiration catheter was placed
into the abscess cavity for drainage.
Disseminated infection occurred in one patient
with bullous pemphigoid who presented with
fever, cough, dyspnoea, purulent expectoration,
headache and loss of consciousness. The chest
radiograph and chest CT scan revealed bilateral
lung involvement. A contrast-enhanced CT brain
scan showed a large lesion with surrounding
oedema in the right frontoparietal region. The
patient underwent urgent cranial surgery and
evacuation of the cerebral abscess. Cultures of
sputum and the abscess specimen were positive
for Nocardia farcinica. Despite antibiotic therapy,
the patient died because of disseminated nocar-
diosis on the 37th day of hospitalisation.
In total, ten isolates of Nocardia spp. were
obtained from nine patients. Two isolates from
one patient belonged to the same species. Nocar-
dia was isolated from cerebral abscess specimens,
bronchoscopy ﬂuid and ⁄ or sputum samples. Six
isolates were identiﬁed as N. farcinica and four as
members of the Nocardia asteroides complex.
Comparative 16S rRNA gene sequence studies
identiﬁed two speciﬁc subgroups of the N. astero-
ides complex, namely Nocardia cyriacigeorgica
(three isolates) and Nocardia arthritidis (one iso-
late). All isolates were susceptible to imipenem
Table 2. In-vitro susceptibility
results, using a disk diffusion meth-
od, for isolates of Nocardia spp
Antibiotics
Isolates (n = 10)
Overall
Susceptibility %
N. asteroides
(n = 4)
N. farcinicaa
(n = 6)
Susceptibleb Resistant Susceptible Resistant
Ampicillin 0 4 0 6 0
Amoxycillin–
clavulanate
2 2 6 0 80
Ciproﬂoxacin 2 2 4 2 60
Erythromycin 2 2 0 6 20
Trimethoprim–
sulphamethoxazole
3 1 0 6 30
Amikacin 4 0 6 0 100
Tobramycin 4 0 0 6 40
Minocycline 4 0 1 5 50
Cefamandole 3 1 0 6 30
Cefotaxime 4 0 1 5 50
Imipenem 4 0 6 0 100
Linezolid 1 0 2 0 100
aTwo N. farcinica isolates with the same biochemical and antibiotic susceptibility proﬁles that were recovered from
the cerebral abscess and cerebrospinal ﬂuid of the same individual were considered to be identical.
bIsolates in the intermediate category were considered susceptible.
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and amikacin, but resistant to ampicillin
(Table 2).
All patients received medical treatment and
ﬁve cases of cerebral nocardiosis underwent
additional surgery. In four patients, the initial
therapy of ceftriaxone plus amikacin was
replaced by imipenem (one patient) or merope-
nem (three patients) following susceptibility test
results. All intravenous antibiotic therapy was
continued for 30 days and was then replaced by
oral co-trimoxazole (three patients) or co-amoxi-
clav (ﬁve patients) for 6–12 months in patients
who survived. Maintenance therapy was contin-
ued for a median of 180 days (range 20–365 days).
Three patients relapsed with nocardiosis, and one
of these patients died of the disease. Treatment for
the other two relapsed patients was extended to
12 months. The initial antibiotics were ineffective
in four of the nine patients, two of whom
relapsed; three of these patients survived initially,
but one died following disseminated infection.
The overall mortality in this series was 33% (three
of nine). All previously healthy patients with
nocardiosis showed complete recovery after treat-
ment for 6 months.
Previous studies [3,11–16] have found that
N. asteroides is the predominant species associated
with nocardiosis, especially in immunosup-
pressed patients [12–15]. However, the predom-
inant species in the present study was N. farcinica,
which is considered to be the most virulent
Nocardia sp. [8]. Infection in immunosuppressed
hosts is often caused by N. asteroides [2,3,13], and
most of the immunosuppressed patients in the
present series were infected with members of the
N. asteroides complex. Three of these immunosup-
pressed patients had pulmonary infection, two
had cerebral infection and one had disseminated
nocardiosis.
Early diagnosis of nocardiosis is difﬁcult, and
diagnosis is usually delayed because of the
absence of pathognomonic symptoms or a typical
radiological pattern. As in the present study,
N. farcinica is often resistant to third-generation
cephalosporins and sulphonamides, which are
commonly selected as initial therapy for these
infections [17]. An optimal management protocol
has not been deﬁned, although a combination of
imipenem and amikacin may be the therapy of
choice for immunocompromised patients. Ther-
apy should be continued for at least 1 year in
immunosuppressed patients to avoid relapse.
Consistent with previous reports, three (33%)
deaths occurred, two of which were attributable
directly to nocardiosis. Total mortality rates
appear to vary between 11% and 48% [18–20],
although this may differ from the attributable
mortality. A limitation of the present study was
the small number of patients with nocardiosis and
the focus on a single geographical region in
Central Anatolia. However, although these
epidemiological and microbiological results may
not be applicable to other regions, it seems that
non-asteroides Nocardia spp. can be a signiﬁcant
cause of infection, especially in patients with a
predisposing factor.
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ABSTRACT
Several studies have demonstrated that patho-
genic and therapeutic differences exist among
hepatitis B virus (HBV) genotypes. Therefore, this
study established the prevalence of different HBV
genotypes in 128 Belgian patients with chronic
HBV infection. The prevalences of genotypes A
and D, and mixed genotypes A and D, were 53%,
37% and 8%, respectively, for a group of blood
donors, and 54%, 31% and 9%, respectively, for a
group of patients from the gastroenterology units.
The results indicated that genotypes A and D are
the predominant genotypes in Belgian patients
with chronic HBV infection.
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Worldwide, c. 2 billion individuals show evidence
of past or current infection with hepatitis B virus
(HBV), and 350 million individuals are estimated
to have chronic infection. The virus can cause
acute hepatitis and various forms of chronic
infection, ranging from an asymptomatic chronic
carrier state to chronic hepatitis, liver cirrhosis
and hepatocellular carcinoma [1,2]. HBV is a
DNA virus with a partially circular double-stran-
ded genome of c. 3200 bp, consisting of four
overlapping open reading frames: the surface (S)
gene, encoding the virus envelope; the core (C)
gene, encoding the nucleocapsid; the X gene,
encoding the X protein; and the polymerase (P)
gene, encoding a polymerase with reverse tran-
scriptase activity [3,4].
Based on an intergroup divergence of ‡ 8% of
the entire nucleotide sequence, HBV has been
classiﬁed into eight (A–H) genotypes [5–8] with
geographically distinct distributions [3,6–8].
Although some studies have not found an associ-
ation between genotype and clinical outcome or
response to therapy [9,10], others have demon-
strated pathogenic and therapeutic differences
among the genotypes [1,11–14]. Therefore, the
aim of the present study was to establish the
prevalence of the different HBV genotypes in
Belgium.
Two groups of patients were included in the
study. Group I (n = 1564) comprised individuals
who had been rejected as blood donors following
initial screening. These sera were collected
between 1991 and 2002 at Flemish transfusion
centres. Demographic data and clinical informa-
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